Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.25 USD | +0.31% | +12.46% | +83.62% |
May. 14 | Taysha Gene Therapies Q1 Net Loss Narrows, Revenue Declines -- Shares Down After Hours | MT |
May. 14 | Transcript : Taysha Gene Therapies, Inc., Q1 2024 Earnings Call, May 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+83.62% | 608M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+40.01% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- TSHA Stock
- News Taysha Gene Therapies, Inc.
- Chardan Adjusts PT on Taysha Gene Therapies to $7 From $5 as Gene Therapy for Rett Syndrome Shows 'Sustained Benefit', Keeps Buy Rating